NCT07448935Recruiting
One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS
Source: ClinicalTrials.gov · Last updated 6 May 2026
Brief summary (registry, in English)
By detailed sequence analysis and subsequent biophysical characterization of prototypic light chains, this project aims to identify sequence fingerprints in IGLV1-44 light chains leading to AL amyloidosis and POEMS syndrome. This understanding might help improve the risk stratification and early diagnosis of patients overexpressing pathologic IGLV1-44 LCs. Moreover, the development of nanobodies efficient in recognizing and stabilizing IGLV1-44 light chains which exert direct toxicity in cardiac AL amyloidosis and POEMS syndrome might form the basis for future development of therapeutic agents capable of counteracting IGLV1-44 light chain proteotoxicity.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 26 Feb 2026
- Start date
- 28 Nov 2025
- Primary completion date
- 30 Jun 2026
- Lead sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
- Diseases
- Amyloidosis, Multiple myeloma
- NCT number
- NCT07448935
What you commit to
- Study type: Observational
- Planned participants: 100
- From 28 Nov 2025 to the primary completion date, 30 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients fulfilling the criteria for complete hematologic response after anti-clonal therapy
Other illness
- Failure to show willingness to allow use of clinical data and diagnostic leftovers of clinical specimens for research purposes.
Age
- Age \<18 years
Other
- Undefined monoclonal gammopathy or non-AL amyloidosis
Who the study is looking for
- Biopsy-proven diagnosis of systemic AL amyloidosis, POEMS syndrome or multiple myeloma
- Planned peripheral blood sampling +/- bone marrow aspiration
- Age \> 18 years
- Willingness to allow use of clinical data and diagnostic leftovers of clinical specimens for research purposes through signing a written informed consent.
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fondazione IRCCS Policlinico San Matteo Coordinator of this site? Confirm its status | Pavia | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.